FARINA, DEBORAH
 Distribuzione geografica
Continente #
NA - Nord America 1.455
EU - Europa 1.301
AS - Asia 758
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 1
OC - Oceania 1
Totale 3.521
Nazione #
US - Stati Uniti d'America 1.452
CN - Cina 358
UA - Ucraina 254
IE - Irlanda 251
GB - Regno Unito 175
TR - Turchia 171
SE - Svezia 165
SG - Singapore 157
FR - Francia 131
IT - Italia 109
DE - Germania 93
FI - Finlandia 61
IN - India 54
RU - Federazione Russa 38
CZ - Repubblica Ceca 12
IR - Iran 10
EU - Europa 5
BE - Belgio 4
CA - Canada 2
GR - Grecia 2
KR - Corea 2
RS - Serbia 2
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
EG - Egitto 1
HK - Hong Kong 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
LB - Libano 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
TW - Taiwan 1
Totale 3.521
Città #
Chandler 310
Jacksonville 304
Dublin 250
Southend 152
Singapore 132
Princeton 106
Izmir 92
Nanjing 89
Beijing 78
Ashburn 64
Dearborn 58
Wilmington 57
Cambridge 49
Altamura 36
Nanchang 33
Santa Clara 33
New York 30
Shenyang 21
Ann Arbor 19
Hebei 14
Jiaxing 14
Kunming 14
Tianjin 14
Washington 14
Hangzhou 13
Woodbridge 13
Boardman 12
Changsha 12
Chieti 12
Grevenbroich 12
Brno 11
Helsinki 11
Jinan 11
Los Angeles 11
Norwalk 10
Guangzhou 9
Ardabil 8
Augusta 8
San Mateo 7
Campobasso 6
Lanzhou 6
Monmouth Junction 6
Leawood 5
Ningbo 5
Brussels 4
Changchun 4
Houston 4
Montesilvano Marina 4
Taizhou 4
Teramo 4
London 3
Mumbai 3
Munich 3
Orange 3
San Vito Chietino 3
Tappahannock 3
Torino 3
Zhengzhou 3
Belgrade 2
Bologna 2
Düsseldorf 2
Florence 2
Frankfurt am Main 2
Hanover 2
Isernia 2
Moscow 2
Naples 2
Palo Alto 2
Rome 2
Walnut 2
Aachen 1
Amman 1
Andover 1
Ascoli Piceno 1
Atlanta 1
Auburn Hills 1
Bangalore 1
Berlin 1
Cairo 1
Centrale 1
Chengdu 1
Duncan 1
Edinburgh 1
Espoo 1
Genova 1
Hobart 1
Hong Kong 1
Islington 1
Kemerovo 1
Manila 1
Meitingen 1
Mexico City 1
Monte di Procida 1
Mountain View 1
Nürnberg 1
Olomouc 1
Ottawa 1
Parrano 1
Pescara 1
Phoenix 1
Totale 2.273
Nome #
A lipidomic investigation for the caracterisation of CSF lipid profile in patients with multiple sclerosis 100
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 98
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 92
Metabolomics analysis of cerebrospinal fluid reveals a distintive biochemical alteration associated with multiple sclerosis. 91
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 91
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 88
Increasing age at disability milestones among MS patients in the MSBase Registry 86
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 85
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 83
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 83
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 82
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. 81
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 79
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 78
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 75
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 74
Brain tissue loss occurs after suppression of enhancement in patients with multiple scerosis treated with autologous haematopoietic stem cell transplantation. 73
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 73
Development of methods for lipid extraction from CSF and application of mass spectometry techniques for the characterization of the lipid profile and neurosteroids levels in MS patients 73
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 73
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 71
Interferone beta: effetti collaterali 70
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 70
Cognitive dysfunction in patients with relapsing-remitting Multiple Sclerosis 70
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 69
Mass spectrometry based metabonomics of the cerebrospinalfluid highlights a correlation between polar lipids and carnitines levels in multiple sclerosis patients. 68
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 68
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial 66
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 66
Natalizumab-associated PML-IRIS: the Chieti experience. 66
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis 65
JCV-Ab serostatus in MS patients treated with Natalizumab 65
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 65
Interferone beta1b: bilancio su un gruppo di 30 pazienti 64
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 64
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 63
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 63
Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study 61
Autologous HSCT for severe progressive Multiple Sclerosis in a multicenter trial: impact on disease activity and quality of life 61
Lymphomononuclear cells from multiple scerosis patients spontaneously produce high levels of oncostatin M, tumor necrosis factors alpha and beta, and interferon gamma. 61
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. 60
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 57
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 57
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study 57
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 56
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 56
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis 48
Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis 48
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 46
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis 43
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 41
Long-term efficacy and tolerability of natalizumab treatment in multiple sclerosis patients: a multicentre experience in Italy 38
Totale 3.581
Categoria #
all - tutte 14.376
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.376


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020369 0 0 0 0 0 55 91 63 13 57 86 4
2020/2021304 50 2 53 0 17 62 1 3 33 28 45 10
2021/2022205 0 4 6 48 6 2 5 19 12 2 30 71
2022/2023773 55 118 43 77 85 158 39 54 102 6 22 14
2023/2024391 33 18 24 6 28 162 72 3 1 7 2 35
2024/2025310 59 95 109 13 13 21 0 0 0 0 0 0
Totale 3.581